{"title":"Drug clinical trial of COVID-19 in China: A brief analysis","authors":"X. Mu, Y. Zhao, L. Zhang, Y. Cui, Y. Zhang, G. Du","doi":"10.12092/J.ISSN.1009-2501.2020.08.005","DOIUrl":null,"url":null,"abstract":"AIM: To provide suggestion for research and development of drugs against coronavirus disease 2019 (COVID-19) by analyzing the characteristics of the drug clinical trial registration information of COVID-19 in China METHODS: The clinical trials of COVID-19 were searched from Chinese Clinical Trial Registry, and the type, purpose, and design of the studies were analyzed RESULTS: Totally 271 drug clinical trials have been registered till July 1st, 2020 Most of the drugs are marketed ones, including chemical drugs, traditional Chinese medicines, and biologics Combined applications were adopted in some projects Randomized or non-randomized parallel control trials were conducted in most projects Others included single arm, sequential, and factorial design CONCLUSION: To deal with the epidemic, it is important to conduct emergent drug clinical trials to find out effective drugs as soon as possible However, some weaknesses and deficiencies on trials design, conduct and supervision were exposed in the drug clinical trials against COVID-19 It is suggested to enhance the scientific evaluation of candidate drugs, standardize the investigator initiated trials, and establish the national multi-subject research and development platform, and the collaborative and innovative key-task tackling mechanism, thus to improve the ability and level of antiviral drug research and development","PeriodicalId":9961,"journal":{"name":"中国临床药理学与治疗学","volume":"25 1","pages":"869-877"},"PeriodicalIF":0.0000,"publicationDate":"2020-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国临床药理学与治疗学","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12092/J.ISSN.1009-2501.2020.08.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
AIM: To provide suggestion for research and development of drugs against coronavirus disease 2019 (COVID-19) by analyzing the characteristics of the drug clinical trial registration information of COVID-19 in China METHODS: The clinical trials of COVID-19 were searched from Chinese Clinical Trial Registry, and the type, purpose, and design of the studies were analyzed RESULTS: Totally 271 drug clinical trials have been registered till July 1st, 2020 Most of the drugs are marketed ones, including chemical drugs, traditional Chinese medicines, and biologics Combined applications were adopted in some projects Randomized or non-randomized parallel control trials were conducted in most projects Others included single arm, sequential, and factorial design CONCLUSION: To deal with the epidemic, it is important to conduct emergent drug clinical trials to find out effective drugs as soon as possible However, some weaknesses and deficiencies on trials design, conduct and supervision were exposed in the drug clinical trials against COVID-19 It is suggested to enhance the scientific evaluation of candidate drugs, standardize the investigator initiated trials, and establish the national multi-subject research and development platform, and the collaborative and innovative key-task tackling mechanism, thus to improve the ability and level of antiviral drug research and development
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
